Efficacy and safety of twice-daily olopatadine –mometasone combination nasal spray (GSP301) in the treatment of allergic rhinitis: a systematic review and meta-analysis
ConclusionGSP301 is a safe and well-tolerated medication. It showed short-term benefits for seasonal and perennial AR, but may not help to improve patients ’ quality of life and rhinitis control in the long run. (Source: European Archives of Oto-Rhino-Laryngology)
Source: European Archives of Oto-Rhino-Laryngology - March 18, 2022 Category: ENT & OMF Source Type: research
Geographic Variation in Otolaryngologist Intranasal Steroid Prescribing Patterns Among Medicare Beneficiaries
CONCLUSIONS: INCS prescriptions by otolaryngologists and the number of INCS beneficiaries have increased between 2013 and 2017. Over the same time period, the costs of fluticasone and triamcinolone have decreased while the cost of mometasone increased. Total providers by state correlated with claims per state. Additionally, average annual temperature was positively correlated with INCS claims per beneficiary in each state.PMID:35176893 | DOI:10.1177/00034894221079094 (Source: The Annals of Otology, Rhinology, and Laryngology)
Source: The Annals of Otology, Rhinology, and Laryngology - February 18, 2022 Category: ENT & OMF Authors: Franklin M Wu Ruben Ulloa Ido Badash Kevin Hur Source Type: research
Geographic Variation in Otolaryngologist Intranasal Steroid Prescribing Patterns Among Medicare Beneficiaries
CONCLUSIONS: INCS prescriptions by otolaryngologists and the number of INCS beneficiaries have increased between 2013 and 2017. Over the same time period, the costs of fluticasone and triamcinolone have decreased while the cost of mometasone increased. Total providers by state correlated with claims per state. Additionally, average annual temperature was positively correlated with INCS claims per beneficiary in each state.PMID:35176893 | DOI:10.1177/00034894221079094 (Source: The Annals of Otology, Rhinology, and Laryngology)
Source: The Annals of Otology, Rhinology, and Laryngology - February 18, 2022 Category: ENT & OMF Authors: Franklin M Wu Ruben Ulloa Ido Badash Kevin Hur Source Type: research
Geographic Variation in Otolaryngologist Intranasal Steroid Prescribing Patterns Among Medicare Beneficiaries
CONCLUSIONS: INCS prescriptions by otolaryngologists and the number of INCS beneficiaries have increased between 2013 and 2017. Over the same time period, the costs of fluticasone and triamcinolone have decreased while the cost of mometasone increased. Total providers by state correlated with claims per state. Additionally, average annual temperature was positively correlated with INCS claims per beneficiary in each state.PMID:35176893 | DOI:10.1177/00034894221079094 (Source: The Annals of Otology, Rhinology, and Laryngology)
Source: The Annals of Otology, Rhinology, and Laryngology - February 18, 2022 Category: ENT & OMF Authors: Franklin M Wu Ruben Ulloa Ido Badash Kevin Hur Source Type: research
Geographic Variation in Otolaryngologist Intranasal Steroid Prescribing Patterns Among Medicare Beneficiaries
CONCLUSIONS: INCS prescriptions by otolaryngologists and the number of INCS beneficiaries have increased between 2013 and 2017. Over the same time period, the costs of fluticasone and triamcinolone have decreased while the cost of mometasone increased. Total providers by state correlated with claims per state. Additionally, average annual temperature was positively correlated with INCS claims per beneficiary in each state.PMID:35176893 | DOI:10.1177/00034894221079094 (Source: The Annals of Otology, Rhinology, and Laryngology)
Source: The Annals of Otology, Rhinology, and Laryngology - February 18, 2022 Category: ENT & OMF Authors: Franklin M Wu Ruben Ulloa Ido Badash Kevin Hur Source Type: research
A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma
Adv Ther. 2022 Jan 24. doi: 10.1007/s12325-021-02025-w. Online ahead of print.ABSTRACTA novel, once-daily (o.d.), fixed-dose combination (FDC) of indacaterol acetate (IND), glycopyrronium bromide (GLY), and mometasone furoate (MF), delivered by the inhaler Breezhaler® device, is the first long-acting beta2-adrenergic agonist/long-acting muscarinic antagonist/inhaled corticosteroid (LABA/LAMA/ICS) therapy to be approved for maintenance treatment of asthma in adults inadequately controlled on LABA/ICS. The approval of IND/GLY/MF in the European Union (EU) also included an optional electronic sensor and smartphone (or other ...
Source: Adv Data - January 24, 2022 Category: Epidemiology Authors: Dominic Brittain Peter D'Andrea Emilie Gruen Motoi Hosoe Devendra Jain Juergen Jauernig Abhijit Pethe Emil Scosyrev Ana-Maria Tanase Hanns-Christian Tillmann Source Type: research
A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma
AbstractA novel, once-daily (o.d.), fixed-dose combination (FDC) of indacaterol acetate (IND), glycopyrronium bromide (GLY), and mometasone furoate (MF), delivered by the inhaler Breezhaler® device, is the first long-acting beta2-adrenergic agonist/long-acting muscarinic antagonist/inhaled corticosteroid (LABA/LAMA/ICS) therapy to be approved for maintenance treatment of asthma in adults inadequately controlled on LABA/ICS. The approval of IND/GLY/MF in the European Union (EU) also included a n optional electronic sensor and smartphone (or other suitable device) application, making it the first “digital companion”...
Source: Advances in Therapy - January 24, 2022 Category: Drugs & Pharmacology Source Type: research
Phosphodiesterase 4 (PDE4) gene expression in atopic dermatitis patients, before and after treatment with topical mometasone cream
ConclusionOur study indicates that there is an increased level of PDE4 in AD lesions, suggesting that PDE4 plays an important role in the pathogenesis of AD. Targeting PDE4 (using PDE4 inhibitors) may herald a new era in the treatment of AD. (Source: European Journal of Dermatology)
Source: European Journal of Dermatology - January 1, 2022 Category: Dermatology Source Type: research
POSB87 Carbon Footprint Impact of Breezhaler ® Dry Powder Inhaler for Asthma: An Analysis in UK and Italy
Policy interventions to reduce climate impacts are being increasingly considered by healthcare decision-makers in many countries, such as the National Health Service in England and Ministero della transizione ecologica in Italy. Dry powder inhalers (DPIs) for the treatment of asthma demonstrated significantly lower greenhouse gas emissions than pressurised metered-dose inhalers. An analysis was conducted to estimate the reduction in carbon dioxide equivalent (CO2e) emissions related to once-daily indacaterol acetate/mometasone furoate (IND/MF) and once-daily indacaterol acetate/mometasone furoate/glycopyrronium bromide (IN...
Source: Value in Health - January 1, 2022 Category: International Medicine & Public Health Authors: A Choubey, J Marvel, R Ishikawa, H Kaur, A Tedeschi, D Ritrovato, S Sydnor, P Thokala Source Type: research
Effect of topical florfenicol, terbinafine and mometasone furoate ear drops on adrenocortical function in healthy small breed dogs with bilateral otitis externa
CONCLUSIONS AND CLINICAL RELEVANCE: Results demonstrated no evidence of adrenocortical suppression, suggesting that there is no need to delay adrenocortical function testing in dogs treated with topical florfenicol/terbinafine/mometasone furoate when applied as per the manufacturer's recommendations.PMID:34904763 | DOI:10.1111/vde.13051 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - December 14, 2021 Category: Veterinary Research Authors: Sarrah Hoppers Elizabeth Drake Linda A Frank Xiaocun Sun Source Type: research
Effect of topical florfenicol, terbinafine and mometasone furoate ear drops on adrenocortical function in healthy small breed dogs with bilateral otitis externa
CONCLUSIONS AND CLINICAL RELEVANCE: Results demonstrated no evidence of adrenocortical suppression, suggesting that there is no need to delay adrenocortical function testing in dogs treated with topical florfenicol/terbinafine/mometasone furoate when applied as per the manufacturer's recommendations.PMID:34904763 | DOI:10.1111/vde.13051 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - December 14, 2021 Category: Veterinary Research Authors: Sarrah Hoppers Elizabeth Drake Linda A Frank Xiaocun Sun Source Type: research
Effect of topical florfenicol, terbinafine and mometasone furoate ear drops on adrenocortical function in healthy small breed dogs with bilateral otitis externa
CONCLUSIONS AND CLINICAL RELEVANCE: Results demonstrated no evidence of adrenocortical suppression, suggesting that there is no need to delay adrenocortical function testing in dogs treated with topical florfenicol/terbinafine/mometasone furoate when applied as per the manufacturer's recommendations.PMID:34904763 | DOI:10.1111/vde.13051 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - December 14, 2021 Category: Veterinary Research Authors: Sarrah Hoppers Elizabeth Drake Linda A Frank Xiaocun Sun Source Type: research
Effect of topical florfenicol, terbinafine and mometasone furoate ear drops on adrenocortical function in healthy small breed dogs with bilateral otitis externa
CONCLUSIONS AND CLINICAL RELEVANCE: Results demonstrated no evidence of adrenocortical suppression, suggesting that there is no need to delay adrenocortical function testing in dogs treated with topical florfenicol/terbinafine/mometasone furoate when applied as per the manufacturer's recommendations.PMID:34904763 | DOI:10.1111/vde.13051 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - December 14, 2021 Category: Veterinary Research Authors: Sarrah Hoppers Elizabeth Drake Linda A Frank Xiaocun Sun Source Type: research
Effect of topical florfenicol, terbinafine and mometasone furoate ear drops on adrenocortical function in healthy small breed dogs with bilateral otitis externa
CONCLUSIONS AND CLINICAL RELEVANCE: Results demonstrated no evidence of adrenocortical suppression, suggesting that there is no need to delay adrenocortical function testing in dogs treated with topical florfenicol/terbinafine/mometasone furoate when applied as per the manufacturer's recommendations.PMID:34904763 | DOI:10.1111/vde.13051 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - December 14, 2021 Category: Veterinary Research Authors: Sarrah Hoppers Elizabeth Drake Linda A Frank Xiaocun Sun Source Type: research
